Beam Therapeutics Inc. (BEAM) Moving Averages: 50-Day and 200-Day

The closing price of Beam Therapeutics Inc. (NASDAQ: BEAM) was $34.51 for the day, down -1.82% from the previous closing price of $35.15. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 1083049 shares were traded. BEAM stock price reached its highest trading level at $35.59 during the session, while it also had its lowest trading level at $34.03.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.



Our analysis of BEAM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 04 when Simon Amy sold 11,654 shares for $29.70 per share. The transaction valued at 346,115 led to the insider holds 69,308 shares of the business.

Evans John M. sold 6,493 shares of BEAM for $188,904 on Apr 04. The CEO now owns 1,117,979 shares after completing the transaction at $29.09 per share. On Apr 04, another insider, Burrell Terry-Ann, who serves as the Chief Financial Officer of the company, sold 2,186 shares for $29.09 each. As a result, the insider received 63,598 and left with 47,117 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2.49B and an Enterprise Value of 1.59B. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.64 while its Price-to-Book (P/B) ratio in mrq is 3.27. Its current Enterprise Value per Revenue stands at 20.73 whereas that against EBITDA is -4.60.

Stock Price History:

Over the past 52 weeks, BEAM has reached a high of $73.27, while it has fallen to a 52-week low of $28.04. The 50-Day Moving Average of the stock is 32.05, while the 200-Day Moving Average is calculated to be 43.07.

Shares Statistics:

BEAM traded an average of 980.26K shares per day over the past three months and 1.06M shares per day over the past ten days. A total of 72.27M shares are outstanding, with a floating share count of 69.16M. Insiders hold about 1.50% of the company’s shares, while institutions hold 87.10% stake in the company. Shares short for BEAM as of Apr 27, 2023 were 12.73M with a Short Ratio of 12.73M, compared to 13.61M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 17.05% and a Short% of Float of 22.16%.

Earnings Estimates

The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of -$1.15 and a low estimate of -$1.73, while EPS last year was -$1.02. The consensus estimate for the next quarter is -$1.43, with high estimates of -$1.15 and low estimates of -$1.81.

Analysts are recommending an EPS of between -$4.69 and -$6.74 for the fiscal current year, implying an average EPS of -$5.63. EPS for the following year is -$5.93, with 15 analysts recommending between -$4.36 and -$7.81.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $25M to a low estimate of $5M. As of the current estimate, Beam Therapeutics Inc.’s year-ago sales were $16.65M, an estimated increase of 8.40% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $18.05M, an increase of 127.30% over than the figure of $8.40% in the same quarter last year. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $5M.

A total of 14 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $99.2M, while the lowest revenue estimate was $24M, resulting in an average revenue estimate of $74.01M. In the same quarter a year ago, actual revenue was $60.92M, up 21.50% from the average estimate.